Ocriplasmin zur Behandlung der symptomatischen vitreomakulären Traktion mit und ohne Makulaforamen

Maier, Mathias; Abraham, S.; Frank, Christiane; Feucht, Nikolaus; Lohmann, Chris P.

doi:10.1007/s00347-015-0073-z

Cited by 21 publications

(10 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We found higher VMT release rates than the MIVI-TRUST trials (56.6 vs. 26.5%) that are in line with previous series investigated by several authors with release rates ranging from 30 to 71% [7,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29] and may arise from a favorable patient sample: few patients with ERM (11.0%), only 3.6% of patients with adhesion diameter >1,500 µm and 72.3% of patients with phakic eyes. In fact, 12 eyes in our sample fitted the ideal characteristics described by Haller et al [13] (age <65 years, absence of ERM, phakic, adhesion diameter ≤1,500 µm and FTMH ≤250) and had a release rate of 91.7% (n = 11).…”

Section: Discussionsupporting

confidence: 80%

“…In the MIVI-TRUST trials, 40.6% of FTMH achieved closure, while recent series achieved closure rates of 13-80% [14,15,16,17,20,21,22,23,24,25,26,27,28,29,31]. In our study, 50.0% of eyes with FTMH achieved closure, while most of them, 83%, achieved VMT resolution as well.…”

Section: Discussionmentioning

confidence: 64%

“…Interestingly, following the MIVI-TRUST trials, several authors described some small series (10-58 eyes) from the real clinical setting with higher resolution rates after ocriplasmin injection, ranging from 30 to 71% [7,14,15,16,17,18,19,20,21,22,23,24,25,26,27,28,29]. Still, real-life experience data is limited and usually from single-center retrospective studies.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

The Portuguese Experience with Ocriplasmin in Clinical Practice

Figueira

Martins²,

Pessoa³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

Aim: Evaluate the real-life experience with ocriplasmin on vitreomacular traction (VMT) release and full-thickness macular hole (FTMH) closure in Portugal. Methods: Multicentric, retrospective study of 83 eyes of 78 patients who were treated with intravitreal ocriplasmin for VMT with and without FTMH. Primary outcomes were VMT release and FTMH closure. Secondary outcomes included visual acuity changes and structural features on spectral-domain ocular coherence tomography. Results: VMT resolved in 47 of the 83 eyes (56.6%) and 6 of the 12 FTMH were closed (50.0%). Mean best-corrected visual acuity (BCVA) improved from 65.1 at baseline to 70.8 ETDRS letters at the end of follow-up (p < 0.0001) with a mean follow-up of 138.8 days. Improvement in BCVA was significantly better in eyes with VMT release (p = 0.021). Approximately 73% of patients had normal ellipsoid zone integrity at the end of follow-up, 87% had no neurosensorial detachment and 40% had no intra- or subretinal fluid. Conclusion: VMT release and FTMH closure were achieved in more than half of the treated eyes and were correlated with significant BCVA improvements and favorable baseline characteristics. In fact, if a careful patient selection is carried out, VMT resolution with ocriplasmin can be optimized, tailoring the best approach to each patient.

show abstract

Section: Discussionsupporting

confidence: 80%

Section: Discussionmentioning

confidence: 64%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Portuguese Experience with Ocriplasmin in Clinical Practice

Figueira

Martins²,

Pessoa³

et al. 2016

Ophthalmic Res

View full text Add to dashboard Cite

show abstract

“…Clinical reports and small case series raised concern on potential side effects of the enzyme. These studies reported on clinical symptoms and findings including varying degrees of retinal dysfunction, such as visual acuity loss, dyschromatopsia, nyctalopia, visual field constriction, outer retinal signal abnormalities or defects on spectral domain optical coherence tomography, macular hole enlargement, macular detachment with subretinal fluid accumulation, and electroretinography changes [6,7,12,13,14,19,20,21,22,23,24,25]. …”

Section: Discussionmentioning

confidence: 99%

“…Compared to pars plana vitrectomy with peeling of the internal limiting membrane (ILM), which was the only treatment option until recently, intravitreal ocriplasmin injection provides a generally well-tolerated therapeutic intervention for patients with VMT [6,7]. There are numerous potential advantages of pharmacologic vitreolysis over surgical vitrectomy, such as avoidance of surgical risks, faster visual rehabilitation, and induction of a complete posterior vitreous detachment without remnants of vitreous cortex collagen on the ILM.…”

Section: Introductionmentioning

confidence: 99%

Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment

Vielmuth

Schumann²,

Spindler³

et al. 2016

Ophthalmologica

View full text Add to dashboard Cite

Purpose: To assess the stiffness of the human internal limiting membrane (ILM) and evaluate potential changes of mechanical properties following intravitreal ocriplasmin injection for vitreomacular traction. Methods: This is an interventional comparative case series of 12 surgically excised ILM specimens consecutively obtained from 9 eyes of 9 patients after unsuccessful pharmacologic vitreolysis with ocriplasmin. During the same time period, 16 specimens from 13 other eyes without ocriplasmin treatment were harvested during vitrectomy and served as controls. All patients presented with macular holes or vitreomacular traction and underwent vitrectomy with ILM peeling either with or without brilliant blue (BB) staining. All specimens were analyzed using atomic force microscopy with scan regions of 25 × 25 μm. In all specimens, both the retinal side and vitreal side of the ILM were analyzed. Results: Atomic force microscopy revealed no significant differences in elasticity of ILM specimens removed from eyes with or without ocriplasmin treatment. Undulated areas of the retinal side presented stiffer than the vitreal side of the ILM. Topographical mapping of both the vitreal and retinal side of the ILM showed no apparent alteration of the morphology in ocriplasmin-treated eyes compared to untreated eyes. Staining with BB resulted in an increase of tissue stiffness. Conclusions: Intravitreal injection of ocriplasmin does not change biomechanical properties of the human ILM. There is no evidence of a potential enzymatic effect of ocriplasmin interfering with the stiffness of this basement membrane.

show abstract

Das Makulaforamen

Haritoglou

2023

Springer Reference Medizin

View full text Add to dashboard Cite

Ocriplasmin zur Behandlung der symptomatischen vitreomakulären Traktion mit und ohne Makulaforamen

Cited by 21 publications

References 29 publications

The Portuguese Experience with Ocriplasmin in Clinical Practice

The Portuguese Experience with Ocriplasmin in Clinical Practice

Biomechanical Properties of the Internal Limiting Membrane after Intravitreal Ocriplasmin Treatment

Das Makulaforamen

Contact Info

Product

Resources

About